MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Prime Medicine, Inc. (PRME)

Prime Medicine, Inc. (PRME)

|||

Balance Sheets Overview

Current Ratio
305.45%
Quick Ratio
305.45%
Cash Ratio
149.73%
Debt to Asset Ratio
84.02%
Unit: Thousand (K) dollars
Assets Breakdown
    • Operating lease right-of-use ass...
    • Cash and cash equivalents
    • Restricted cash
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Operating lease liability, net o...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
47,451
64,106
63,032
71,396
Short-term investments-Nonrelated Party
-
-
114,648
137,030
Short-term investments-Related Party
-
-
0
4,861
Short-term investments
47,620
71,391
-
-
Prepaid expenses
1,357
1,971
2,939
2,493
Other current assets
376
421
674
15,626
Total current assets
96,804
137,889
181,293
231,406
Property and equipment, net
17,077
18,816
20,572
22,046
Operating lease right-of-use assets
120,468
123,334
126,177
117,869
Restricted cash
13,691
13,691
13,691
13,691
Other assets
1,000
1,000
1,000
-
Total assets
249,040
294,730
342,733
385,012
Accounts payable
5,808
12,325
8,887
9,354
Accrued expenses and other current liabilities
8,978
8,098
12,600
11,000
Deferred revenue related party
7,934
7,320
7,824
6,951
Operating lease liability
8,972
8,546
8,137
7,714
Total current liabilities
31,692
36,289
37,448
35,019
Deferred revenue, net of current related party
56,033
57,775
58,127
59,751
Operating lease liability, net of current
103,506
105,966
108,290
110,421
Research and development funding liability
18,000
18,000
18,000
18,000
Total liabilities
209,231
218,030
221,865
223,191
Common stock, par value of 0.00001 per share 775,000,000 shares authorized 180,737,548 and 180,514,014 shares issued and outstanding as of june30, 2026 and december31, 2025, respectively
2
2
2
2
Additional paid-in capital
1,019,401
1,014,175
1,009,138
1,004,061
Accumulated other comprehensive (loss) income
-9
-1
82
33
Accumulated deficit
-979,585
-937,476
-888,354
-842,275
Total stockholders equity
39,809
76,700
120,868
161,821
Total liabilities and stockholders equity
249,040
294,730
342,733
385,012
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Short-term investments$47,620K Cash and cashequivalents$47,451K (-11.81%↓ Y/Y)Prepaid expenses$1,357K (-55.24%↓ Y/Y)Other current assets$376K (-97.71%↓ Y/Y)Operating leaseright-of-use assets$120,468K (0.22%↑ Y/Y)Total current assets$96,804K (-20.19%↓ Y/Y)Property and equipment,net$17,077K (-28.33%↓ Y/Y)Restricted cash$13,691K (0.00%↑ Y/Y)Other assets$1,000K Total assets$249,040K (-10.74%↓ Y/Y)Total liabilities andstockholders equity$249,040K (-10.74%↓ Y/Y)Total liabilities$209,231K (-4.09%↓ Y/Y)Total stockholdersequity$39,809K (-34.59%↓ Y/Y)Accumulated deficit-$979,585K (-23.73%↓ Y/Y)Accumulated othercomprehensive (loss) income-$9K (10.00%↑ Y/Y)Operating leaseliability, net of current$103,506K (-7.98%↓ Y/Y)Deferred revenue, net ofcurrent related party$56,033K (-5.92%↓ Y/Y)Total currentliabilities$31,692K (-7.09%↓ Y/Y)Research and developmentfunding liability$18,000K (50.00%↑ Y/Y)Additional paid-in capital$1,019,401K (19.57%↑ Y/Y)Common stock, par valueof 0.00001 per...$2K (0.00%↑ Y/Y)Accrued expenses andother current...$8,978K (-26.16%↓ Y/Y)Operating lease liability$8,972K (23.62%↑ Y/Y)Deferred revenue relatedparty$7,934K (-4.58%↓ Y/Y)Accounts payable$5,808K (-8.94%↓ Y/Y)